Mavrilimumab for severe COVID-19 - Authors' reply.

ABSTRACT:

SUBMITTER: De Luca G 

PROVIDER: S-EPMC7837188 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature